COVID19 Impact on Deep Brain Stimulation in Parkinson's Disease Market 2021-2027: Industry Insight and Growth Strategy by Business Players - Abbott, Medtronic, Boston Scientific, Nevro

The report covers a forecast and an analysis of the Deep Brain Stimulation in Parkinson’s Disease Market on a global and regional level. The study provides historical data for 2018, 2019, and 2020 along with a forecast from 2019 to 2027 based on revenue and volume.

Overview of the Global Deep Brain Stimulation in Parkinson’s Disease Market:

The report spread across 150 pages is an overview of the Global Deep Brain Stimulation in Parkinson’s Disease Market. This report study based on the Deep Brain Stimulation in Parkinson’s Disease Market. It is a complete overview of the market, covering various aspects prevailing market landscape. It accumulates comprehensive information and research methodologies. Deep Brain Stimulation in Parkinson’s Disease Market Research Report is a meticulous investigation of current scenario of the market, which covers several market dynamics.

The Global Deep Brain Stimulation in Parkinson's Disease Market is accounted for $678.89 Million in 2019 and is expected to reach $1,509.07 Million by 2027 growing at a CAGR of 10.5% during the forecast period.

Get a Sample Copy of this Report @ https://marketprognosis.com/sample-request/20730 .

According to the market report analysis, Deep brain stimulation (DBS) is a neurosurgical procedure involving the placement of a medical device called a neurostimulator (sometimes referred to as a "brain pacemaker"), which sends electrical impulses, through implanted electrodes, to specific targets in the brain. DBS is used to manage some of the symptoms of Parkinson's Disease that cannot be adequately controlled with medications. It is recommended for people who have PD with motor fluctuations and tremor inadequately controlled by medication, or to those who are intolerant to medication, as long as they do not have severe neuropsychiatric problems. 

The most important key factors driving the growth of the Global Deep Brain Stimulation in Parkinson’s Disease Market are increasing incidence of neurological disorders, such as Parkinson’s disease (PD) and supportive government policies and laws of the countries. However, a surgical side effect is restraining the market growth.

Purchase this report online with 150 Pages, Top Key Players Analysis and List of Tables & Figure @ https://marketprognosis.com/buyReport/20730 .

Major Key Players:

1 Abbott    

2 Aleva Neurotherapeutics

3 Beijing PINS Medical

4 Boston Scientific

5 Functional Neuromodulation

6 Medtronic   

7 Neuronetics

8 NeuroPace

9 Nevro

Market Segment by Products:

1 Dual Channel Deep Brain Stimulator

2 Single Channel Deep Brain Stimulator

Market Segment by End Users:

1 Ambulatory Surgical Centers (ASCs)

2 Hospitals

3 Neurology Clinics

4 Research Centers   

Request a Discount on standard prices of this premium report @ https://marketprognosis.com/discount-request/20730 .

Global Business News:

Medtronic (June 29, 2021) - Medtronic Launches App-Based Study to Better Understand Relationship Between Atrial Fibrillation Disease Burden and Impact on Patient Outcomes - Medtronic plc, the global leader in medical technology, today announced the initiation of the DEFINE AFib study, the company's first app-based research study. Using data collected from the LINQ family of insertable cardiac monitors (ICMs), the study aims to address unanswered questions around atrial fibrillation (AF) burden and its impact on patient outcomes, quality of life, and healthcare utilization. The first patients in the study were enrolled at Duke University Medical Center in Durham, N.C., by Jonathan Paul Piccini, M.D., MHS, FHRS, director of Cardiac Electrophysiology and associate professor of medicine at Duke University School of Medicine, and at Florida Electrophysiology Associates in Atlantis, Fla., by Robert S. Fishel, M.D., founder of the practice and director of Electrophysiology at JFK Medical Center.

DEFINE AFib will be conducted remotely through the new Medtronic Discovery App in coordination with U.S. sites that collectively will enroll approximately 5,000 patients. Study participants will include patients age 22 or older who have a history of AF, an iPhone device (iOS version 13 or higher), and one of the LINQ family of ICMs, among other criteria. The study will incorporate both device data and patient-reported data derived from scheduled patient surveys and the HealthKit - coupled with electronic health record information about medications and previous cardiac procedures - to provide comprehensive, actionable insights. Through a machine learning approach, aggregated study data will be leveraged to enable improved AF management in the future.

"When it comes to managing atrial fibrillation, there is not a 'one-size-fits-all' approach, and the hope is that DEFINE AFib may give us the tools to help personalize AF management based on a patient's individual health profile and physiology," said Dr. Piccini, who is also chair of the DEFINE AFib Steering Committee. "DEFINE AFib will harness the power of digital health to make fundamental discoveries about how we can manage atrial fibrillation better in each and every one of our patients."

Table of Contents:

1 Executive Summary        

2 Prefaces         

3 Deep Brain Stimulation in Parkinson’s Disease Market Trend Analysis       

4 Porters Five Force Analysis       

5 Global Deep Brain Stimulation in Parkinson’s Disease Market, By Product Type    

6 Global Deep Brain Stimulation in Parkinson’s Disease Market, By Application    

7 Global Deep Brain Stimulation in Parkinson’s Disease Market, By End User     

8 Global Deep Brain Stimulation in Parkinson’s Disease Market, By Geography      

9 Company Profiling

Contact us:

ProgMark Pvt. Ltd.

Thane – 421501

India.

info@marketprognosis.com

sales@marketprognosis.com

+1 973 241 5193

https://www.marketprognosis.com

This release was published on openPR.